<code id='ECD22E6B79'></code><style id='ECD22E6B79'></style>
    • <acronym id='ECD22E6B79'></acronym>
      <center id='ECD22E6B79'><center id='ECD22E6B79'><tfoot id='ECD22E6B79'></tfoot></center><abbr id='ECD22E6B79'><dir id='ECD22E6B79'><tfoot id='ECD22E6B79'></tfoot><noframes id='ECD22E6B79'>

    • <optgroup id='ECD22E6B79'><strike id='ECD22E6B79'><sup id='ECD22E6B79'></sup></strike><code id='ECD22E6B79'></code></optgroup>
        1. <b id='ECD22E6B79'><label id='ECD22E6B79'><select id='ECD22E6B79'><dt id='ECD22E6B79'><span id='ECD22E6B79'></span></dt></select></label></b><u id='ECD22E6B79'></u>
          <i id='ECD22E6B79'><strike id='ECD22E6B79'><tt id='ECD22E6B79'><pre id='ECD22E6B79'></pre></tt></strike></i>

          Home / comprehensive / focus

          focus


          focus

          author:leisure time    Page View:938
          Adobe

          LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma acquisitions that are bolstering hopes for the industry’s year ahead.

          The deal includes up to another $400 million in payments if certain milestones are met.

          advertisement

          Aiolos was launched just last year, based in both San Francisco and London. The company, which announced a $245 million Series A round in October, has been readying a Phase 2 trial of its candidate AIO-001 in adult asthma.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In